Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28

NCT00204594 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: rM28
DRUG: autologous PBMCs

Sponsor

University Hospital Tuebingen